Identification of prostate-specific antigen (PSA) isoforms in complex biological samples utilizing complementary platforms.

Measurements of the prostate-specific antigen (PSA) levels in blood are widely used as diagnostic, predictive and prognostic marker of prostate disease. The selective detection of molecular forms of PSA can contribute clinically to meaningful enhancements of the conventional PSA-test. As it is plausible that an in-depth search for structural variants of PSA gene products may increase our ability to discriminate distinct patho-biological basis and stages of prostate diseases, we have developed a multi-step protocol comprising gel-based methods followed by mass spectrometric identification. Our current aim was to provide a comprehensive identification of PSA variants occurring in seminal fluid. We provide a proof-of-principle for this multiple step analytical approach to identify multiple PSA variants from complex biological samples that revealed distinct molecular characteristics. In addition, sequence-annotated protein bands in SDS-PAGE gels were compared to those detected by Western blots, and by monitoring the enzymatic activity in zymogram gels, using gelatin as a substrate. The high accuracy annotations were obtained by fast turnaround MALDI-Orbitrap analysis from excised and digested gel bands. Multiple PSA forms were identified utilizing a combination of MASCOT and SEQUEST search engines.

[1]  R. Gittes,et al.  Prostate-specific antigen. , 1987, The New England journal of medicine.

[2]  K. Slawin,et al.  Seminal plasma contains “BPSA,” a molecular form of prostate‐specific antigen that is associated with benign prostatic hyperplasia , 2000, The Prostate.

[3]  E. Diamandis,et al.  Ultrasensitive bioanalytical assays using time-resolved fluorescence detection. , 1995, Pharmacology & therapeutics.

[4]  H. Lilja,et al.  Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. , 1995, Clinical chemistry.

[5]  C. Belluco,et al.  Prostate carcinoma and green tea: PSA‐triggered basement membrane degradation and MMP‐2 activation are inhibited by (−)epigallocatechin‐3‐gallate , 2004, International journal of cancer.

[6]  H. Lilja,et al.  Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. , 1997, Biochemical and biophysical research communications.

[7]  Eleftherios P. Diamandis,et al.  Human Kallikrein-related Peptidase 14 (KLK14) Is a New Activator Component of the KLK Proteolytic Cascade , 2008, Journal of Biological Chemistry.

[8]  J Leinonen,et al.  Prostate-specific antigen. , 1999, Seminars in cancer biology.

[9]  H. Huland,et al.  Molecular Heterogeneity of Free PSA in Sera of Patients with Benign and Malignant Prostate Tumors , 1999, European Urology.

[10]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[11]  N Heuzé,et al.  Molecular cloning and expression of an alternative hKLK3 transcript coding for a variant protein of prostate-specific antigen. , 1999, Cancer research.

[12]  H. Lilja,et al.  Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. , 1994, European journal of biochemistry.

[13]  J. Clements,et al.  Kallikrein-related peptidase (KLK) family mRNA variants and protein isoforms in hormone-related cancers: do they have a function? , 2006, Biological chemistry.

[14]  Andrew J. Vickers,et al.  Prostate-specific antigen and prostate cancer: prediction, detection and monitoring , 2008, Nature Reviews Cancer.

[15]  H. Lilja,et al.  Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. , 1987, The Journal of clinical investigation.

[16]  O. Nilsson,et al.  Prostate-specific antigen in serum occurs predominantly in complex with alpha 1-antichymotrypsin. , 1991, Clinical chemistry.

[17]  H. Lilja,et al.  Protein C inhibitor in human body fluids. Seminal plasma is rich in inhibitor antigen deriving from cells throughout the male reproductive system. , 1992, The Journal of clinical investigation.

[18]  H. Lilja,et al.  Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. , 1990, European journal of biochemistry.

[19]  J. Gilabert,et al.  Functionally active protein C inhibitor/plasminogen activator inhibitor-3 (PCI/PAI-3) is secreted in seminal vesicles, occurs at high concentrations in human seminal plasma and complexes with prostate-specific antigen. , 1991, Thrombosis research.

[20]  H. Lilja A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. , 1985, The Journal of clinical investigation.

[21]  J. Hugosson,et al.  Discrimination of prostate cancer from benign disease by plasma measurement of intact, free prostate-specific antigen lacking an internal cleavage site at Lys145-Lys146. , 2001, Clinical chemistry.

[22]  H. Lilja,et al.  Molecular cloning of human prostate specific antigen cDNA , 1987, FEBS letters.

[23]  K. Watt,et al.  Human prostate-specific antigen: structural and functional similarity with serine proteases. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Mary Ann Comunale,et al.  Glycomic characterization of prostate-specific antigen and prostatic acid phosphatase in prostate cancer and benign disease seminal plasma fluids. , 2009, Journal of proteome research.

[25]  K. Fujikawa,et al.  Characterization of the Precursor of Prostate-specific Antigen , 1997, The Journal of Biological Chemistry.